Feedback
Settings

Settings

Goto Application

334,830 results
Offices all Languages Stemming false Single Family Member true Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:G01N33/48

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1 / 33,483
1.WO/2022/107017A SYSTEM AND METHOD FOR PROVIDING TEST RESULTS
WO - 27.05.2022
Int.Class G16H 50/20
GPHYSICS
16INFORMATION AND COMMUNICATION TECHNOLOGY SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
HHEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
50ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
20for computer-aided diagnosis, e.g. based on medical expert systems
 Appl.No PCT/IB2021/060654 Applicant NORTH-WEST UNIVERSITY Inventor GROBLER, Magdalena Johanna
This invention relates to methods and systems for providing test results, particularly test results from a PCR test of a biological sample, in an automated fashion. The method comprises receiving test data acquired from medical test equipment and processing the test data with a classifier to determine a corresponding test result automatically with a performance measurement. If the performance measurement associated is below a predetermined threshold, the method comprises transmitting the test data to a clinician, receiving a test result from the clinician; and updating the classification database with the test data and the corresponding test result received from the clinician; and if the performance measurement associated with the classification is above the threshold, randomly selecting and transmitting test data to the clinician; receiving a test result from the clinician; and if necessary, updating the classification database with the test data and the corresponding test result from the clinician.
2.WO/2022/107737SARS-CoV-2 DETECTION KIT AND SARS-CoV-2 DETECTION METHOD
WO - 27.05.2022
Int.Class C07K 16/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses
 Appl.No PCT/JP2021/041983 Applicant FUJIFILM CORPORATION Inventor UJIHARA Dai
The present invention addresses the problem of providing a SARS-CoV-2 detection kit and a SARS-CoV-2 detection method that enable the detection of SARS-CoV-2 in a simple manner and with higher sensitivity. The present invention provides a SARS-CoV-2 detection kit for specifically detecting a nucleocapsid protein (NP) contained in a biological sample, the SARS-CoV-2 detection kit comprising at least one antibody that specifically reacts with a SARS-CoV-2 nucleocapsid protein (NP), wherein the antibody includes at least one antibody of which the subclass is IgG2b, and the kit includes a first container that receives a silver-containing compound, and a second container that receives a reducing agent that can reduce silver ions.
3.WO/2022/105772BISPECIFIC ANTIBODY HAVING NEUTRALIZING ACTIVITY AGAINST CORONAVIRUS, AND USE THEREOF
WO - 27.05.2022
Int.Class C07K 16/46
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
46Hybrid immunoglobulins
 Appl.No PCT/CN2021/131080 Applicant SANYOU BIOPHARMACEUTICALS CO., LTD. Inventor LANG, Guojun
Provided are a bispecific antibody having a neutralizing activity against a coronavirus, and a use thereof. A neutralizing antibody which is against a coronavirus S protein and blocks the binding of the coronavirus S proteins to an ACE 2 receptor is provided to prevent and treat coronaviruses. Specifically provided is an antibody or polypeptide complex specifically binding to a coronavirus S protein, comprising: (a) a first epitope binding moiety comprising a heavy chain variable region VH and a light chain variable region VL, wherein the VH and VL form an antigen binding domain specifically binding to a first epitope of an S protein; and (b) a second epitope binding moiety comprising a single-domain antibody or a VHH fragment thereof specifically binding to a second epitope of the S protein, wherein the first and second epitope binding portions are fused to each other and are not identical to each other. Also provided is a polynucleotide for encoding an antibody or a polypeptide complex and a host cell comprising same, and a method for preparing an antibody or a polypeptide complex. The antibody or polypeptide complex can be used for preventing, treating, diagnosing, and/or detecting coronaviruses.
4.WO/2022/109087REUSABLE CARTRIDGES FOR DETECTING ANALYTES IN SOLUTION
WO - 27.05.2022
Int.Class G01N 33/68
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
68involving proteins, peptides or amino acids
 Appl.No PCT/US2021/059819 Applicant GENENTECH, INC. Inventor POLLOCK, Samuel Benjamin
This disclosure relates to methods of preparing re-usable and dry-able cartridges comprising matrices comprising a detection molecule such as an antibody, for detection or enrichment of an analyte in a sample, such as an antigen recognized by an antibody. In some embodiments, the cartridge comprises a tube or well that holds the matrix. In some embodiments, the matrix or associated cartridges may be stored wet or dry. The disclosure also relates to the cartridges and methods of their use.
5.WO/2022/109327SIALYLATED GLYCOPROTEINS
WO - 27.05.2022
Int.Class G01N 33/68
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
68involving proteins, peptides or amino acids
 Appl.No PCT/US2021/060182 Applicant MOMENTA PHARMACEUTICALS, INC. Inventor WASHBURN, Nathaniel
Methods for measuring disialylated Fc glycan in a biological sample are described.
6.WO/2022/107091DETECTING IMPAIRED PHYSIOLOGICAL FUNCTION FROM EXHALED GAS CONCENTRATIONS AND SPECTRAL ENVELOPE EXTRACTED FROM SPEECH ANALYSIS
WO - 27.05.2022
Int.Class A61B 5/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
BDIAGNOSIS; SURGERY; IDENTIFICATION
5Measuring for diagnostic purposes; Identification of persons
 Appl.No PCT/IB2021/060800 Applicant CORDIO MEDICAL LTD. Inventor SHALLOM, Ilan D.
A method includes computing one or more values of at least one parameter at respective times during an exhalation of a subject (22), based on one or more properties of sound passing through air exhaled by the subject during the exhalation, the parameter being related to a concentration of a gas in the air. The method further includes generating (84) an output in response to the values. Other embodiments are also described.
7.WO/2022/107736BLOOD SAMPLE TESTING METHOD USING TAXIS BEHAVIOR OF NEMATODE
WO - 27.05.2022
Int.Class G01N 33/48
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
 Appl.No PCT/JP2021/041981 Applicant HIROTSU BIO SCIENCE INC. Inventor HIROTSU Takaaki
The present invention provides a blood sample testing method. The present invention provides, for example, a method for testing or analyzing a blood sample from a subject that has cancer or a subject suspected of having cancer, the method involving evaluating the taxis behavior of a nematode with respect to the blood sample. The present invention thereby provides, for example, a method for evaluating whether a subject has cancer.
8.WO/2022/108306METHOD FOR PREPARING IMMUNOGENICITY-ENHANCED CD103+ FCGR3+ DENDRITIC CELL BY TREATMENT WITH INTERLEUKIN-33 AND PHARMACEUTICAL COMPOSITION COMPRISING SAME DENDRITIC CELL FOR CANCER IMMUNOTHERAPY
WO - 27.05.2022
Int.Class C12N 5/0784
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
5Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
07Animal cells or tissues
071Vertebrate cells or tissues, e.g. human cells or tissues
078Cells from blood or from the immune system
0784Dendritic cells; Progenitors thereof
 Appl.No PCT/KR2021/016813 Applicant RESEARCH & BUSINESS FOUNDATION SUNGKYUNKWAN UNIVERSITY Inventor BAE, Yong-Soo
The present invention relates to a method for increasing anti-tumor immunity of a dendrocytic therapeutic agent and, more specifically, to a method for preparing cluster of differentiation 103 (CD103)-positive dendritic cells, CD103-positive dendritic cells prepared by the preparation method, and a pharmaceutical composition and kit comprising same for cancer immunotherapy, the method comprising a step of treating dendrocyte progenitor cells with interleukin-33 (IL-33) when the dendrocyte progenitor cells are cultured in a medium containing FMS-like tyrosine kinase 3 ligand (Flt3L) and thus differentiated to dendritic cells. As the dendritic cells differentiated by the preparation method of the present invention exhibit a high potential of inducing antigen-specific cytotoxic T cells, compared to control dendritic cells, and antitumor immunity is strongly induced by a subpopulation of the newly differentiated dendritic cells, the preparation method of the present invention has the advantage of increasing immunogenicity in the differentiation step in contrast to a convention method of increasing immunogenicity after completion of differentiation to dendritic cells. Therefore, it is expected that novel immune cell therapy capable of greatly increasing a therapeutic effect through the preparation method of the present invention and dendritic cells cultured ex vivo using same can be provided.
9.WO/2022/108741MONITORING MEMBRANE PROTEIN TRAFFICKING FOR DRUG DISCOVERY AND DRUG DEVELOPMENT
WO - 27.05.2022
Int.Class G01N 33/50
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
 Appl.No PCT/US2021/057525 Applicant UNIVERSITY OF HOUSTON SYSTEM Inventor MCCONNELL, Bradley K.
Embodiments of the present disclosure pertain to systems for use in screening at least one binding agent for binding to at least one cell membrane protein. The systems include one or more cells that include the cell membrane protein. The cell membrane protein is genetically engineered to express a first peptide capable of generating a luminescent signal upon interaction with a second peptide. The systems may also include the second peptide. Additional embodiments of the present disclosure pertain to methods of utilizing the systems to screen at least one binding agent for binding to at least one cell membrane protein.
10.WO/2022/108981UNBIASED AND HIGH-THROUGHPUT IDENTIFICATION AND QUANTIFICATION OF HOST CELL PROTEIN IMPURITIES BY AUTOMATED ITERATIVE LC-MS/MS (HCP-AIMS) FOR THERAPEUTIC PROTEIN DEVELOPMENT
WO - 27.05.2022
Int.Class H01J 49/00
HELECTRICITY
01BASIC ELECTRIC ELEMENTS
JELECTRIC DISCHARGE TUBES OR DISCHARGE LAMPS
49Particle spectrometers or separator tubes
 Appl.No PCT/US2021/059642 Applicant REGENERON PHARMACEUTICALS, INC. Inventor HUANG, Yu
The present disclosure generally pertains to methods of identifying and quantitating host cell proteins (HCPs) in therapeutic protein development. In particular, the present invention generally pertains to methods of liquid chromatography-tandem mass spectrometry (LC-MS/MS) for unbiased identification and sensitive quantitation of HCPs in therapeutic protein development.
# -